TuHURA Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TuHURA Biosciences, Inc. - overview
Established
2023
Location
Tampa, FL, US
Primary Industry
Biotechnology
About
Based in Florida, United States, and founded in 2023 by the merger of CohBar, Inc. and Morphogenesis, Inc. , TuHURA Biosciences, Inc. operates as a biotech company providing cancer vaccines and tumor microenvironment modulators for cancer treatment.
In May 2023, In May 2023, CohBar, Inc. , agreed to merge with Morphogenesis, Inc. The transaction is expected to close in Q3 of 2023. The combined entity will operate under the name TuHURA Biosciences, Inc.
, and will be a publicly listed entity. Following the deal, CohBar, Inc. and Morphogenesis, Inc. shareholders are expected to own approximately 15% and 77% stake, respectively, in the combined entity.
TuHURA Biosciences, Inc. develops immunotherapies in treating cancer for improving effectiveness. The company developed immune Fx (IFx) personalized cancer vaccines and tumor microenvironment (TME) modulators.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Biotechnology, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.